Table 5.

Summary of survival results. PFS: progression-free survival.

	Patients treated with non-NGS-based therapy	Patients with NGS based therapy	Patients with PFS2 and PFS1 data
	N = 89	N = 48	N = 137
PFS of the 1st treatment - months	3.6 [0.5–33.8]	3.3 [0.5–10.1]	3.5 [0.5–33.8]
PFS of the 2nd treatment - months	2.1 [0.03–18]	2.3 [0.2–10.1]	2.2 [0.03–18]
Ratio 2nd PFS/ 1st PFS
Median [range]	0,6 [0.003–3,6]	0,6 [0.1–6,1]	0.6 [0.003–6.1]
⩽ 1.3	66 (74%)	36 (75%)	102 (74%)
> 1.3	23 (26%)	12 (25%)	35 (26%)